These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 32629143)

  • 61. ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.
    Kim YH; Her AY; Jeong MH; Kim BK; Hong SJ; Kim S; Ahn CM; Kim JS; Ko YG; Choi D; Hong MK; Jang Y
    Angiology; 2020 Feb; 71(2):139-149. PubMed ID: 31694385
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Endovascular management as first therapy for chronic total occlusion of the lower extremity arteries: comparison of balloon angioplasty, stenting, and directional atherectomy.
    Gallagher KA; Meltzer AJ; Ravin RA; Graham A; Shrikhande G; Connolly PH; Aiello F; Dayal R; McKinsey JF
    J Endovasc Ther; 2011 Oct; 18(5):624-37. PubMed ID: 21992631
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers: New-onset diabetes mellitus stratified by statin use.
    Shin J; Kim H; Yim HW; Kim JH; Lee S; Kim HS
    J Clin Pharm Ther; 2022 Jan; 47(1):97-103. PubMed ID: 34668200
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Angioedema related to Angiotensin inhibitors.
    Knecht SE; Dunn SP; Macaulay TE
    J Pharm Pract; 2014 Oct; 27(5):461-5. PubMed ID: 25124378
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Impact of Angiotensin Converting Enzyme Inhibitors/Angiotensin Receptors Blockers on Mortality in Acute Heart Failure Patients with Left Ventricular Systolic Dysfunction in the Middle East: Observations from the Gulf Acute Heart Failure Registry (Gulf CARE).
    Al-Zakwani I; Sulaiman K; Al-Lawati JA; Alsheikh-Ali AA; Panduranga P; Al-Habib KF; Al Suwaidi J; Al-Mahmeed W; Al-Faleh H; Elasfar A; Al-Motarreb A; Ridha M; Bulbanat B; Al-Jarallah M; Bazargani N; Asaad N; Amin H
    Curr Vasc Pharmacol; 2018; 16(6):596-602. PubMed ID: 28820057
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Myocardial Infarction Patients With Renal Dysfunction.
    Evans M; Carrero JJ; Szummer K; Åkerblom A; Edfors R; Spaak J; Jacobson SH; Andell P; Lindhagen L; Jernberg T
    J Am Coll Cardiol; 2016 Apr; 67(14):1687-97. PubMed ID: 27056774
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Effect of continuing angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers on the day of surgery on myocardial injury after non-cardiac surgery: A retrospective cohort study.
    Kim J; Lee S; Choi J; Ryu DK; Woo S; Park M
    J Clin Anesth; 2024 Jun; 94():111401. PubMed ID: 38330844
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers in acute ST-segment elevation myocardial infarction patients with diabetes mellitus undergoing percutaneous coronary intervention.
    Choi SY; Choi BG; Rha SW; Byun JK; Shim MS; Li H; Mashaly A; Choi CU; Park CG; Seo HS; Oh DJ; Jeong MH;
    Int J Cardiol; 2017 Dec; 249():48-54. PubMed ID: 28867244
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events and residual renal function in dialysis patients: a meta-analysis of randomised controlled trials.
    Liu Y; Ma X; Zheng J; Jia J; Yan T
    BMC Nephrol; 2017 Jun; 18(1):206. PubMed ID: 28666408
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Low body mass index is a risk factor for hyperkalaemia associated with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers treatments.
    Hirai T; Yamaga R; Fujita A; Itoh T
    J Clin Pharm Ther; 2018 Dec; 43(6):829-835. PubMed ID: 29908131
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Angiotensin converting enzyme inhibitors maintain polytetrafluroethylene graft patency.
    Sajgure A; Choudhury A; Ahmed Z; Choudhury D
    Nephrol Dial Transplant; 2007 May; 22(5):1390-8. PubMed ID: 17267534
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Prognostic Impact of Angiotensin-Converting Enzyme Inhibitors and Receptor Blockers on Recurrent Ventricular Tachyarrhythmias and Implantable Cardioverter-Defibrillator Therapies.
    Schupp T; Behnes M; Weiß C; Nienaber C; Lang S; Reiser L; Bollow A; Taton G; Reichelt T; Ellguth D; Engelke N; Bertsch T; Akin M; Mashayekhi K; Borggrefe M; Akin I
    J Cardiovasc Pharmacol; 2019 May; 73(5):272-281. PubMed ID: 30747784
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Impact of diabetes, angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker use, and statin use on presentation and outcomes in patients with giant cell arteritis.
    Ma J; Khalidi N; Wierzbicki O; Alqutami A; Ioannidis G; Pagnoux C
    Int J Rheum Dis; 2020 Aug; 23(9):1233-1239. PubMed ID: 32776676
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A retrospective study of the effects of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in diabetic nephropathy.
    Pathak JV; Dass EE
    Indian J Pharmacol; 2015; 47(2):148-52. PubMed ID: 25878372
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Effect of calcium channels blockers and inhibitors of the renin-angiotensin system on renal outcomes and mortality in patients suffering from chronic kidney disease: systematic review and meta-analysis.
    Zhao HJ; Li Y; Liu SM; Sun XG; Li M; Hao Y; Cui LQ; Wang AH
    Ren Fail; 2016 Jul; 38(6):849-56. PubMed ID: 27055479
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Angiotensin-converting enzyme inhibitors reduce albuminuria more than angiotensin receptor blockers in patients with type 2 diabetes.
    Al-Sayed NA; Gao T; Wells BJ; Yu C; Zimmerman RS
    Endocr Pract; 2013; 19(4):579-86. PubMed ID: 23425642
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Angiotensin Converting-Enzyme Inhibitors, Angiotensin Receptor Blockers, and Calcium Channel Blockers Are Associated with Prolonged Vascular Access Patency in Uremic Patients Undergoing Hemodialysis.
    Chen FA; Chien CC; Chen YW; Wu YT; Lin CC
    PLoS One; 2016; 11(11):e0166362. PubMed ID: 27832203
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A Modern History RAAS Inhibition and Beta Blockade for Heart Failure to Underscore the Non-equivalency of ACEIs and ARBs.
    Hyman DA; Siebert VR; Birnbaum GD; Alam M; Birnbaum Y
    Cardiovasc Drugs Ther; 2020 Apr; 34(2):215-221. PubMed ID: 32219664
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system.
    Toh S; Reichman ME; Houstoun M; Ross Southworth M; Ding X; Hernandez AF; Levenson M; Li L; McCloskey C; Shoaibi A; Wu E; Zornberg G; Hennessy S
    Arch Intern Med; 2012 Nov; 172(20):1582-9. PubMed ID: 23147456
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Comparison of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Management Strategies Before Cardiac Surgery: A Pilot Randomized Controlled Registry Trial.
    van Diepen S; Norris CM; Zheng Y; Nagendran J; Graham MM; Gaete Ortega D; Townsend DR; Ezekowitz JA; Bagshaw SM
    J Am Heart Assoc; 2018 Oct; 7(20):e009917. PubMed ID: 30371293
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.